Antiarrhythmic effects of newly developed propafenone derivatives
Abstract
It is well known that the presence of different chemical groups in drug molecules influences their pharmacological properties. The aim of our study is to investigate whether newly synthesized derivatives of propafenone, with changes in benzyl moiety, have a different effect upon arrhythmia, compared to propafenone. 5OCl-PF and 5OF-PF are derivatives of propafenone with -Cl or –F substituent on the ortho position of the benzyl moiety. For verification of their antiarrhythmic effect, we used an in vivo rat model of aconitine-induced arrhythmia. 5OCl-PF speeded the appearance of supraventricular premature beats (SVPB) and death more than aconitine. All animals treated with 5OCl-PF developed ventricular premature beats in salvos (VPBS), bigeminies (VPBB) and paroxysmal ventricular tachycardia (PVT). 5OF-PF had a negative chronotropic effect and potentiated atrial excitability (more SVPB). It had a positive effect on the occurrence and onset time of supraventricular tachycardia, VPBS, and PVT. Based on the obtained results, it can be concluded that newly synthesized propafenone derivatives have no better antiarrhythmic effect than the parent compound. In the future, our research will be focused on the synthesis of different derivatives and examining their antiarrhythmic effects.
References
Fischer M. Propafenon-ein Antiarrhythmikum der neuen Generation. Med Klin. 1980;75(1):39-41.
Funck-Brentano C, Kroemer HK, Lee JT, Roden DM. Propafenone. N Engl J Med. 1990;322(8):518-25.
Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent onset atrial fibrillation. J Am Coll Cardiol. 2001;37(2):542-7.
Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(1):104-23.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5);373-498.
Morganroth J, Bigger JT Jr. Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial. Am J Cardiol. 1990;65(22):1497-503.
Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331(12):785-91.
Sweetman SC. Martindale 36th ed. London: Pharmaceutical Press; 2009. 3694 p.
Brembilla-Perrot B, Houriez P, Beurrier D, Claudon O, Terrier de la Chaise A, Louis P. Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias. Int J Cardiol. 2001;80(1):7-15.
Francisco F, Palazzolo J, Arce M, Arrieta M. Proarrhythmia Induced by Propafenone: What is the Mechanism? Indian Pacing Electrophysiol J. 2010;10(6):278-80.
Baker JG, Hill SJ, Summers RJ. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011;32(4):227-34.
Madeja M, Steffen W, Mesic I, Garic B, Zhorov BS. Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1. J Biol Chem. 2010;285(44):33898-905.
Thai KM, Windisch A, Stork D, Weinzinger A, Schiesaro A, Guy RH, et al. The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives. Chem Med Chem. 2010;5(3):436-42.
Madeja M, Leicher T, Friederich P, Punke MA, Haverkamp W, Musshoff U, et al. Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1. Mol Pharmacol. 2003;63(3):547-56.
Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD. A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem. 2003;46(7):1250-6.
Choe H, Nah KH, Lee SN, Lee HS, Lee HS, Jo SH, et al. A novel hypothesis for the binding mode of HERG channel blockers. Biochem Biophys Res Commun. 2006;344(1):72-8.
Arcangeli A, Becchetti A. New Trends in Cancer Therapy: Targeting Ion Channels and Transporters. Pharmaceuticals. 2010;3(4):1202-24.
Ivkovic B, Sokovic M, Markovic B, Vladimirov S. Synthesis and evaluation of derivatives of phenylpropiophenone as potential antibacterial and antifungal agents. In: Mátyus P, Wölfling J, editors. Hungarian-Austrian-Czech-German-Greek-Italian-Polish-Slovak-Slovenian Joint Meeting on Medicinal Chemistry. Bologna, Italy: Medimond SRL; 2009; p. 61-4.
Bogdarin IA, Kozin VV, Men'kova IE, Shirokova NIu. Absorption of fatty acids by the rat heart in arrhythmia. Patol Fiziol Eksp Ter. 2008;4:14-6.
Bartosova L, Novak F, Bebarova M, Frydrych M, Brunclik V, Opatrilova R, et al. Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia -- compared to lidocaine. Eur J Pharmacol. 2007;575(1-3):127-33.
Winslow E. Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity. Br J Pharmacol. 1980;71(2):615-22.
Lu HR, De Clerck F. R 56 865, a Na+/Ca(2+)-overload inhibitor, protects against aconitine-induced cardiac arrhythmias in vivo. J Cardiovasc Pharmacol. 1993;22(1):120-5.
Catterall WA. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol. 1980;20:15–43.
Muroi M, Kimura I, Kimura M. Blocking effects of hypoaconite and aconitine on nerve action potentials in phrenic nervediaphragm muscles of mice. Neuropharmacology. 1990;29(6):567-72.
Friese J, Gleitz J, Gutser UT, Heubach JF, Matthiesen T, Wilffert B, et al. Aconitum sp. Alkaloids: the modulation of voltage-dependent Na+ channels, toxicity and antinociceptive properties. Eur J Pharmacol. 1997;337(2-3):165-74.
Peper K, Trautwein W. The effect of aconitine on the membrane current in cardiac muscle. Pflugers Arch Gesamte Physiol Menschen Tiere. 1967;296(4):328-36.
Tanz RD, Robbins JB, Kemple KL, Allen PA. Pharmacology of aconitine-induced automaticity of cat papillary muscle. I. Effect of dose, tension, rate and endogenous catecholamines. J Pharmacol Exp Ther. 1973;185(3):427-37.
Bartošova L, Novak F, Frydrych M, Parak T, Opatřilova R, Brunclik V, et al. Effect of a new ultrashort betalytic agent on aconitine-induced arrhythmia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149(2):339-43.
Sampson KJ, Kass RS. Anti-Arrhythmic Drugs. In: Brunton LL, Chabner BA and Knollmann BC, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics, 12th edition. New York: The McGraw-Hill; 2011; p. 815-49.
Tamargo J, Valenzuela C, Delpón E. New insights into the pharmacology of sodium channel blockers. Eur Heart J. 1992;13 Suppl F:2-13.
Delgado C, Tamargo J, Henzel D, Lorente P. Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Br J Pharmacol. 1993;108(3):721-7.
Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J. 1984;5(2):115-25.
Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A. Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol. 1981;3(6):1162-73.
Delgado C, Tamargo J, Tejerina T, Valenzuela C. Effects of 5-hydroxy-propafenone in guinea-pig atrial fibres. Br J Pharmacol. 1987;90(3):575-82.
Bergmann M, Bolte H. Elektrophysiologische Untersuchmegen mit Propafenon an myokardialen Einzelfasern. In: Hochrein H, Hapke HJ, Beck, editors. Fortschritte in der Pharmakotherapie von Herzrhythmusstorungen. Stuttgart, New York: Fischer Verlag; 1977; p. 29-34.
Kohlhardt M. Der Finflup von Propafenon auf den transmembrandren Na+-und Ca2+-Strom der Warblutter-Myokard-fasermembran. In: Hochrein H, Hapke HJ, Beck, editors. Forschritte in der Pharmakotherapie von Herzrhythmusstorungen. Stuttgart, New York: Fischer Verlag; 1977; p. 35-8.
Kohlhardt M. A quantitative analysis of the Na+-dependence of Vmax of the fast action potential in mammalian ventricular myocardium. Saturation characteristics and the modulation of a drug induced INa blockade by [Na+]o. Pflugers Arch. 1982;392(4):379-87.
Kohlhardt M, Seifert C, Hondeghem LM. Tonic and Phasic/Na blockade by antiarrhythmics. Different properties of drug binding to fast sodium channels as judged from Vmax studies with propafenone and derivatives in mammalian ventricular myocardium. Pflugers Arch. 1983;396(3):199-209.
Tamargo J, Delgado C. Electrophysiological effects of propafenone on isolated guinea-pig ventricular muscle and sheep Purkinje fibres. Eur J Pharmacol. 1985;118(3):331-40.
Tamargo J, Delgado C, Tejerina T. Effect of propafenone on ventricular automaticity. Eur Heart J. 1984;5(Suppl. I):131.
Hapke HJ, Prigge E. Zur Pharmakologie von 2'- 12- Hydroxy-3-(propylamino)-propoxy -3-phenylpropiophenon (Propafenon, SA 79) hydrochlorid. Arzneimittelforschung. 1976;26(10):1849-57.
Riou B, Besse S, Lecarpentier Y, Viars P. In vitro effects of propofol on rat myocardium. Anaesth Analg. 1992;76(4):609-16.
Wascher TC, Dittrich P, Kukovetz WR. Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia. Arzneimittelforschung. 1991;41(2):119-24.
Karagueuzian HS, Fujimoto T, Katoh T, Peter T, McCullen A, Mandel WJ. Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine. Circulation. 1982;66(6):1190-8.
